TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Twist Bioscience Corp
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$139.77+7.02 (+5.29%)
Close on Oct 19, 2026
- Market cap
- $8.72B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$111.61 (+396.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Twist Bioscience Corp grew revenue 19.2% to $431.80M over the twelve months to Jun 30, 2026. Free cash flow was -$93.12M.
Revenue
$431.80M
+19.2% vs. a year earlier
Operating income
-$144.98M
TTM Q3 2026
Free cash flow
-$93.12M
TTM Q3 2026
EPS, diluted
-$2.22
TTM Q3 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.72B
- P/E ratio
- –
- Price to sales
- 20.20
- Price to book
- 19.57
- Dividend yield
- –
- Free cash flow yield
- -1.07%
Fundamentals
- Revenue
- $431.80M
- Net income
- -$136.72M
- EPS, diluted
- -$2.22
- Free cash flow
- -$93.12M
- Book value per share
- $7.14
- Diluted shares
- 62M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$431.80M+19.2% YoY
Gross profit
$224.39M+25.8% YoY
Operating income
-$144.98M
Net income
-$136.72M
EPS, diluted
-$2.22
Free cash flow
-$93.12M
Reported periodTrailing twelve months